Hydroxychloroquine Fails as Post-Exposure Prophylaxis for C
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Covid-19 occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.

-- Researchers conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis.
-- They enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure).
-- Within 4 days after exposure, they randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days).

Results:
-- 821 asymptomatic participants were enrolled. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact.
-- The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine and those receiving placebo.
-- Side effects were more common with hydroxychloroquine than with placebo, but no serious adverse reactions were reported.

Conclusively, After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2016638
Dr. T●●●●z H●●●●●●i and 7 others like this15 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
One can only wonder at the inadequacies and non standardised levels of research and clinical trials in India. ICMR proves HCQ to be useful. Lancet proves it useless. Now even NEJM proves HCQ useless. Truly a nightmare,since the flip flops and ping pong being played with HCQ is also being played with the lives of Healthcare workers and patients. And hence,once again,Plasma Therapy must be pursued as our Last defence.... Read more
Jun 4, 2020Like2